Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2024 Sep;47(9):2157-2176.
doi: 10.1007/s40618-024-02366-7. Epub 2024 Apr 18.

Familial states of primary hyperparathyroidism: an update

Affiliations
Review

Familial states of primary hyperparathyroidism: an update

F Cetani et al. J Endocrinol Invest. 2024 Sep.

Abstract

Background: Familial primary hyperparathyroidism (PHPT) includes syndromic and non-syndromic disorders. The former are characterized by the occurrence of PHPT in association with extra-parathyroid manifestations and includes multiple endocrine neoplasia (MEN) types 1, 2, and 4 syndromes, and hyperparathyroidism-jaw tumor (HPT-JT). The latter consists of familial hypocalciuric hypercalcemia (FHH) types 1, 2 and 3, neonatal severe primary hyperparathyroidism (NSHPT), and familial isolated primary hyperparathyroidism (FIHP). The familial forms of PHPT show different levels of PHPT penetrance, developing earlier and with multiglandular involvement compared to sporadic counterpart. All these diseases exhibit Mendelian inheritance patterns, and for most of them, the genes responsible have been identified. DNA testing for predisposing mutations is helpful in index cases or in individuals with a high suspicion of the disease. Early recognition of hereditary disorders of PHPT is of great importance for the best clinical and surgical approach. Genetic testing is useful in routine clinical practice because it will also involve appropriate screening for extra-parathyroidal manifestations related to the syndrome as well as the identification of asymptomatic carriers of the mutation.

Purpose: The aim of the review is to discuss the current knowledge on the clinical and genetic profile of these disorders along with the importance of genetic testing in clinical practice.

Keywords: FHH; FIHP; HPT-JT; MEN1; MEN2; MEN4; NSHPT.

PubMed Disclaimer

References

    1. Jha S, Simonds WF (2023) Molecular and clinical spectrum of primary hyperparathyroidism. Endocr Rev 44(5):779–818 - PubMed - PMC - DOI
    1. Halperin R, Arnon L, Nasirov S, Friedensohn L, Gershinsky M, Telerman A et al (2022) Germline CDKN1B variant type and site are associated with phenotype in MEN4. Endocr Relat Cancer 30:e220174 - PubMed
    1. Chevalier B, Coppin L, Romanet P, Cuny T, Maïza JC, Abeillon J et al (2024) Beyond MEN1, when to think about MEN4? Retrospective study on 5600 patients in the French population and literature review. J Clin Endocrinol Metab 1–12
    1. Seabrook AJ, Harris JE, Velosa SB, Kim E, McInerney-Leo AM, Dwight T et al (2021) Multiple endocrine tumors associated with germline MAX mutations: multiple endocrine neoplasia type 5? J Clin Endocrinol Metab 106(4):1163–1182 - PubMed - DOI
    1. Marx SJ, Goltzman D (2019) Evolution of our understanding of the hyperparathyroid syndromes: a historical perspective. J Bone Min Res 34(1):22–37 - DOI

MeSH terms

LinkOut - more resources